87 related articles for article (PubMed ID: 15157868)
1. A hot spot for protein kinase inhibitor sensitivity.
Bishop AC
Chem Biol; 2004 May; 11(5):587-9. PubMed ID: 15157868
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
3. Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitors.
Boschelli DH; Wang D; Wang Y; Wu B; Honores EE; Barrios Sosa AC; Chaudhary I; Golas J; Lucas J; Boschelli F
Bioorg Med Chem Lett; 2010 May; 20(9):2924-7. PubMed ID: 20363128
[TBL] [Abstract][Full Text] [Related]
4. Development of Src tyrosine kinase substrate binding site inhibitors.
Ye G; Tiwari R; Parang K
Curr Opin Investig Drugs; 2008 Jun; 9(6):605-13. PubMed ID: 18516760
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.
Blencke S; Zech B; Engkvist O; Greff Z; Orfi L; Horváth Z; Kéri G; Ullrich A; Daub H
Chem Biol; 2004 May; 11(5):691-701. PubMed ID: 15157880
[TBL] [Abstract][Full Text] [Related]
6. Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
Wang Y; Shakespeare WC; Huang WS; Sundaramoorthi R; Lentini S; Das S; Liu S; Banda G; Wen D; Zhu X; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Dalgarno D; Clackson T; Sawyer TK
Bioorg Med Chem Lett; 2008 Sep; 18(17):4907-12. PubMed ID: 18691885
[TBL] [Abstract][Full Text] [Related]
7. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
8. Structure-based virtual screening of Src kinase inhibitors.
Lee K; Kim J; Jeong KW; Lee KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
Bioorg Med Chem; 2009 Apr; 17(8):3152-61. PubMed ID: 19321350
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the inhibitor recognition of human Lyn kinase domain.
Miyano N; Kinoshita T; Nakai R; Kirii Y; Yokota K; Tada T
Bioorg Med Chem Lett; 2009 Dec; 19(23):6557-60. PubMed ID: 19857964
[TBL] [Abstract][Full Text] [Related]
10. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
[TBL] [Abstract][Full Text] [Related]
11. ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases.
Nam NH; Lee S; Ye G; Sun G; Parang K
Bioorg Med Chem; 2004 Nov; 12(22):5753-66. PubMed ID: 15498652
[TBL] [Abstract][Full Text] [Related]
12. In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures.
Verkhivker GM
Biopolymers; 2007 Mar; 85(4):333-48. PubMed ID: 17167796
[TBL] [Abstract][Full Text] [Related]
13. Development of selective bisubstrate-based inhibitors against protein kinase C (PKC) isozymes by using dynamic peptide microarrays.
Poot AJ; van Ameijde J; Slijper M; van den Berg A; Hilhorst R; Ruijtenbeek R; Rijkers DT; Liskamp RM
Chembiochem; 2009 Aug; 10(12):2042-51. PubMed ID: 19618415
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH
Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575
[TBL] [Abstract][Full Text] [Related]
15. Structural biology contributions to tyrosine kinase drug discovery.
Cowan-Jacob SW; Möbitz H; Fabbro D
Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
[TBL] [Abstract][Full Text] [Related]
16. Spectroscopic characterization of the SH2- and active site-directed peptide sequences of a bivalent Src kinase inhibitor.
Desamero RZ; Kang J; Dol C; Chinwong J; Walters K; Sivarajah T; Profit AA
Appl Spectrosc; 2009 Jul; 63(7):767-74. PubMed ID: 19589214
[TBL] [Abstract][Full Text] [Related]
17. Design strategies for protein kinase inhibitors.
Parang K; Sun G
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):617-29. PubMed ID: 15503864
[TBL] [Abstract][Full Text] [Related]
18. SRC inhibitors as potential therapeutic agents for human cancers.
Trevino JG; Summy JM; Gallick GE
Mini Rev Med Chem; 2006 Jun; 6(6):681-7. PubMed ID: 16787379
[TBL] [Abstract][Full Text] [Related]
19. A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors.
Aronov AM; Bemis GW
Proteins; 2004 Oct; 57(1):36-50. PubMed ID: 15326593
[TBL] [Abstract][Full Text] [Related]
20. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
Eck MJ; Manley PW
Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
